Regeneron Pharmaceuticals · Total Non-Current Liabilities

REGN Total Non-Current Liabilities

Latest reported$4.49Bperiod endingJun 30, 2026

REGN Quarterly Total Non-Current Liabilities ($11.40M → $4.49B)

Quarterly total non-current liabilities

High-resolution chart · PNG

REGN total non-current liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Regeneron Pharmaceuticals Total Non-Current Liabilities — Quarterly (USD)
Period ending	Total Non-Current Liabilities (USD)
Jun 30, 2026	4,488,600,000
Mar 31, 2026	4,337,500,000
Dec 31, 2025	4,933,400,000
Sep 30, 2025	4,786,500,000
Jun 30, 2025	4,613,300,000
Mar 31, 2025	4,591,000,000
Dec 31, 2024	4,461,500,000
Sep 30, 2024	4,455,000,000
Jun 30, 2024	4,372,400,000
Mar 31, 2024	3,797,600,000
Dec 31, 2023	3,683,700,000
Sep 30, 2023	3,660,300,000
Jun 30, 2023	3,535,200,000
Mar 31, 2023	3,464,600,000
Dec 31, 2022	3,409,200,000
Sep 30, 2022	3,359,800,000
Jun 30, 2022	3,484,100,000
Mar 31, 2022	3,426,400,000
Dec 31, 2021	2,733,500,000
Sep 30, 2021	2,698,700,000
Jun 30, 2021	2,626,200,000
Mar 31, 2021	2,577,400,000
Dec 31, 2020	3,440,600,000
Sep 30, 2020	3,620,700,000
Jun 30, 2020	1,668,900,000
Mar 31, 2020	1,569,300,000
Dec 31, 2019	1,618,900,000
Sep 30, 2019	1,669,500,000
Jun 30, 2019	1,704,600,000
Mar 31, 2019	1,898,700,000
Dec 31, 2018	1,534,400,000
Sep 30, 2018	1,520,083,000
Jun 30, 2018	1,434,364,000
Mar 31, 2018	1,539,312,000
Dec 31, 2017	1,484,700,000
Sep 30, 2017	1,510,994,000
Jun 30, 2017	1,556,618,000
Mar 31, 2017	1,643,073,000
Dec 31, 2016	1,282,726,000
Sep 30, 2016	1,375,587,000
Jun 30, 2016	1,176,837,000
Mar 31, 2016	1,219,654,000
Dec 31, 2015	1,143,133,000
Sep 30, 2015	1,151,058,000
Jun 30, 2015	586,970,000
Mar 31, 2015	691,009,000
Dec 31, 2014	632,761,000
Sep 30, 2014	777,431,000
Jun 30, 2014	735,658,000
Mar 31, 2014	744,080,000
Dec 31, 2013	700,102,000
Sep 30, 2013	681,517,000
Jun 30, 2013	681,120,000
Mar 31, 2013	672,406,000
Dec 31, 2012	671,555,000
Sep 30, 2012	676,023,000
Jun 30, 2012	679,623,000
Mar 31, 2012	685,749,000
Dec 31, 2011	689,580,000
Sep 30, 2011	421,543,000
Jun 30, 2011	432,962,000
Mar 31, 2011	443,950,000
Dec 31, 2010	452,561,000
Sep 30, 2010	460,536,000
Jun 30, 2010	299,854,000
Mar 31, 2010	296,792,000
Dec 31, 2009	250,865,000
Sep 30, 2009	205,584,000
Jun 30, 2009	211,415,000
Mar 31, 2009	167,988,000
Dec 31, 2008	219,034,000
Sep 30, 2008	171,187,000
Jun 30, 2008	176,310,000
Mar 31, 2008	184,319,000
Dec 31, 2007	192,327,000
Sep 30, 2007	325,013,000
Jun 30, 2007	313,691,000
Mar 31, 2007	321,138,000
Dec 31, 2006	323,452,000
Sep 30, 2006	260,015,000
Jun 30, 2006	263,057,000
Mar 31, 2006	266,099,000
Dec 31, 2005	269,142,000
Sep 30, 2005	249,373,000
Jun 30, 2005	251,939,000
Mar 31, 2005	254,577,000
Dec 31, 2004	256,426,000
Sep 30, 2004	257,912,000
Jun 30, 2004	260,672,000
Mar 31, 2004	265,737,000
Dec 31, 2003	268,989,000
Sep 30, 2003	289,563,000
Jun 30, 2003	208,640,000
Mar 31, 2003	205,460,000
Dec 31, 2002	205,475,000
Sep 30, 2002	205,150,000
Jun 30, 2002	205,815,000
Mar 31, 2002	206,437,000
Dec 31, 2001	207,020,000
Sep 30, 2001	9,327,000